A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

Magnus Nakrem Lyngbakken; Jan-Erik Berdal; Arne Eskesen; Dag Kvale; Inge Christoffer Olsen; Corina Silvia Rueegg; Anbjørg Rangberg; Christine Monceyron Jonassen; Torbjørn Omland; Helge Røsjø; Olav Dalgard

doi:10.1038/s41467-020-19056-6

Nature Communications (Oct 2020)

A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

Magnus Nakrem Lyngbakken,
Jan-Erik Berdal,
Arne Eskesen,
Dag Kvale,
Inge Christoffer Olsen,
Corina Silvia Rueegg,
Anbjørg Rangberg,
Christine Monceyron Jonassen,
Torbjørn Omland,
Helge Røsjø,
Olav Dalgard

Affiliations

Magnus Nakrem Lyngbakken: Division of Medicine, Akershus University Hospital
Jan-Erik Berdal: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo
Arne Eskesen: Department of Infectious Diseases, Division of Medicine, Akershus University Hospital
Dag Kvale: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo
Inge Christoffer Olsen: Department of Research Support for Clinical Trials, Oslo University Hospital
Corina Silvia Rueegg: Department of Research Support for Clinical Trials, Oslo University Hospital
Anbjørg Rangberg: Center for Laboratory Medicine, Østfold Hospital Trust
Christine Monceyron Jonassen: Center for Laboratory Medicine, Østfold Hospital Trust
Torbjørn Omland: Division of Medicine, Akershus University Hospital
Helge Røsjø: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo
Olav Dalgard: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo

DOI: https://doi.org/10.1038/s41467-020-19056-6
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 6

Abstract

Read online

The use of hydroxychloroquine therapy for the treatment of Covid-19 is controversial. In this study, Lyngbakken and colleagues present a randomized controlled trial and show that the drug has no antiviral effects in humans infected with SARS-CoV-2.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal